Novel auto-immune therapeutic targets (cell surface/extracellular space) for discovery of antibody drug candidates - Biowebspin | Biowebspin
Logo Biowebspin


The worldwide platform to find industrial partners and funding

External open innovation partner programNovel auto-immune therapeutic targets (cell surface/extracellular space) for discovery of antibody drug candidates

Are you working on auto-immune diseases? Have you identified new targets for antibodies (available in the extracellular space/cell surface) that can be used to improve auto-immune diseases directly or indirectly? Are you interesting in partnering with Argenx to translate your science into a new medicine?
What we are looking for

We are looking for proposals that bring forward novel targets that are causative factors for auto-immune diseases. The target should be secreted, localized in the extracellular matrix or be a transmembrane protein with extracellular domains.

At the preclinical stage, selected molecular targets should be supported by clear scientific data derived from in vitro, ex vivo, or animal models. Molecular targets identified in clinical trials (up to Phase II clinical trial) shall also be considered.

Target should give the opportunity to get first-in-class therapeutics.

What we offer

Argenx is a therapeutic antibody biotechnology company with its proprietary antibody discovery platform. We are active in the area of oncology, immune-oncology and severe auto-immune diseases, and have discovery, preclinical and clinical capabilities.

All proposals will be assessed by our Research & Development team. Based on the level of interest within the Company research portfolio and strategic fit, we will enter into discussion with selected candidate(s), potentially leading to partnership agreements or collaborations.

Proponents that submit proposals of interest will be contacted within 8 weeks of submission to clarify additional details.

In case of matching interests, a mutually beneficial agreement will be established.

What to submit

Submit a proposal in a form which is available online (it takes about 15 minutes). The proposal should be brief, sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). Information about proprietary IP should be provided as well. The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.

Privacy, confidentiality & FAQ

The Company will not share the information beyond its own staff; your initial proposal should contain only non-confidential information.
If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).


Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.

Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website. As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Contact us for more information about the terms and conditions of the matchmaking service of Biowebspin.


argenx is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies. argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases.

The company platform offers the identification of antibodies that allow “unlocking” novel and complex target biology and development of antibody-based drugs designed for longer duration of effect and greater efficacy.

Furthermore, argenx collaborates closely with academic experts, bringing cutting edge antibody discovery technologies to the heart of novel target research. The extraordinary diversity of argenx immune repertoires streamlines target validation, transforming novel monoclonal antibodies proteins into next generation therapeutic antibody programs.